Adaptive Iterative Dose Reduction (ADIR) 3D, the third generation software, will be offered to existing Aquilion One, Premium, and Prime CT customers.
Toshiba America Medical Systems Inc.’s latest dose reduction software, Adaptive Iterative Dose Reduction (ADIR) 3D, has received FDA clearance, the company announced.
The third generation software, which Toshiba will offer to existing Aquilion One, Premium, and Prime CT customers, reduces radiation dose compared to conventional scanning, the company said. The algorithm, designed to work in raw data and imaging data space, reduces noise while attempting to maintain image quality.
The ADIR 3D can be integrated with Sure Exposure 3D, software that calculates the minimum radiation exposure required for every exam based on pre-set targeted level of image quality.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.